• Commerce Secretary Howard Lutnick confirms plan for significantly higher tariffs on imported pharmaceuticals, expected within two weeks.
  • AstraZeneca announces $50 billion U.S. investment to hedge against potential 200% tariffs.
  • Section 232 investigation cites national security concerns, sparking debate over drug prices and supply chain resilience.

U.S. Pharmaceutical Tariffs Loom as Domestic Manufacturing Push Accelerates

The U.S. government is finalizing a plan to impose tariffs as high as 200% on imported pharmaceuticals, Commerce Secretary Howard Lutnick revealed in a CNBC interview. The measures, expected within two weeks, follow a Section 232 investigation into whether reliance on foreign drug manufacturing threatens national security.

"We're going to be higher," Lutnick said of the impending tariff rates, though he declined to specify exact figures. The announcement has already triggered defensive moves from major pharmaceutical firms, with UK-based AstraZeneca pledging a $50 billion, five-year investment in U.S. manufacturing and R&D operations.

The company, which derives 42% of its sales from the U.S., aims to create jobs and expand its domestic presence while mitigating potential trade barriers. "Our new facilities will support next-generation medicines for U.S. and global patients," a company spokesperson said, though AstraZeneca declined to comment specifically on the tariff proposal.

Industry Scrambles as Policy Takes Shape

Pharmaceutical executives have been bracing for the measures since the Section 232 investigation launched last year, using the grace period to accelerate domestic production plans. Analysts suggest the tariffs could fundamentally reshape global supply chains, though immediate disruptions may be limited as companies rush to expand U.S. capacity.

"The administration is playing hardball on reshoring," said one industry insider familiar with the negotiations, speaking anonymously due to the sensitivity of ongoing talks. "But the two-week warning gives firms just enough runway to adjust strategies."

While the FDA has moved to streamline domestic manufacturing approvals, concerns persist about potential short-term price spikes and supply gaps. The policy marks the first application of Section 232 tariffs—previously used for steel and aluminum—to the pharmaceutical sector, setting a precedent that could ripple through other critical industries.

Correction: An earlier version of this article misstated the expected tariff rate range. While sources suggest rates could reach 200%, the exact figures won't be confirmed until the formal announcement.